Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Contract Win

24 Jan 2006 07:01

Sopheon PLC24 January 2006 Embargoed: 24 January 2006, 07:00hrs Sopheon Plc ("Sopheon" or the "Company") The Solae Company Chooses Sopheon to Automate Stage-Gate(R) Process and Support Product Portfolio Decision-Making Accolade System Cited for Capacity to Reduce Business Risk Associated withInnovation Sopheon, the international software and services company, announced today thatThe Solae Company has begun deploying Sopheon's Accolade process and productportfolio management system enterprise-wide to enhance its innovation processesand strengthen innovation-related decision-making support. The Solae Company is an alliance between DuPont and Bunge Ltd. It is a globalleader in the research and application of soy-based food ingredients. As partof a plan for enhancing its innovation processes, Solae elected to adoptStage-Gate, the widely used product development methodology. That decision ledto a search for a technology solution that could both automate Stage-Gate andhelp the company more effectively develop and control its product portfolio. The Solae Company chose the Sopheon system after researching a mix of options.Accolade was selected in part because it offered a disciplined process forcapturing, evaluating and managing product and project ideas. Solae also sawvalue in the software's provision of centralized, real-time visibility toproject details and automated "what if" analysis as a way to increase the speedand quality of portfolio decision-making. The company's choice of Accolade wasfurther based on the solution's capacity to integrate with Design for Six Sigma(DFSS) methodologies that are integral to Solae's innovation processes. "Solae has worked hard to earn its reputation for innovation leadership," saidJonathan McIntyre, vice president of research and development at The SolaeCompany. "But true innovation is inherently risky. It involves reaching beyondthe boundaries of what your customers are able to tell you and anticipating whatthey are going to need, sometimes before they even know it. A principal reasonThe Solae Company chose to adopt the Sopheon system is that it brings consistentrigor to our examination of the business risks and opportunities associated witheach project entering our product development pipeline. Sopheon's Accolade is atool that fits into our larger process for risk management, reducing the chanceof investing in products that the market won't value." "Users often point to how Accolade has increased the flow of innovation intotheir developmental pipeline," said Andy Michuda, chief executive officer ofSopheon. "Solae's perspective focuses on the equally important issue ofensuring that the product ideas an organization invests in are those that havethe greatest potential for success. As a proven innovator, they understand thatthe management of new products is all about ability to make the right businessdecisions. Accolade gives users a competitive edge by helping them reduceuncertainty in choosing the product ideas they are going to back with theircritical R&D resources." Sopheon Accolade(R) is a registered trademark of Sopheon plc. Stage-Gate(R) is a registered trademark of the Product Development Institute,Inc. All other trademarks and registered trademarks are the sole property of their respective owners. About The Solae Company The Solae Company is a global innovator in the research and application of soyprotein. It serves food and beverage manufacturers, dietary supplementdevelopers, retailers and consumers in 100 countries worldwide, providing themwith better ingredients for better living. Headquartered in St. Louis, Missouri,the company was formed through an alliance between Bunge Limited (NYSE: BG) andDuPont (NYSE: DD). For more information, please visit www.solae.com. About Sopheon Sopheon (LSE: SPE) is an international provider of software and services thathelp organizations improve the business impact of product development. TheSopheon Accolade(R) product development system automates gate- or phase-basedproduct development processes and provides strategic decision support thatallows companies to improve innovation, cut product development spending wasteand shorten time-to-market. Sopheon is listed on the AIM Market of the LondonStock Exchange and on the Euronext in the Netherlands. For more information,please visit www.sopheon.com. Press Contacts: Ron Helgeson Bonnie Anderson/Jessica RoeberSopheon Bell Pottinger USA (for Sopheon)Tel.: +1 952 851 7585 Tel.: +1 617 210 4755E-mail: ron.helgeson@sopheon.com E-mail: banderson@bellpottingerusa.com E-mail: jroeber@bellpottingerusa.comAndrew SheaThe Solae Company+1 314 982 1314E-mail: ashea@solae.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Jun 20217:00 amRNSAGM Statement
3rd Jun 20211:50 pmRNSIssue of Equity
2nd Jun 20217:00 amRNSSopheon Deployed Globally at The 3M Company
14th May 202110:11 amRNSGrant of Options / PDMR dealing
14th Apr 20217:00 amRNSLaunch of Accolade for Smart Products
9th Apr 20214:15 pmRNSIssue of Equity
31st Mar 20217:00 amRNSDirectorate Change
29th Mar 20212:30 pmRNSDirector Shareholdings
24th Mar 20217:00 amRNSFinal Results
3rd Mar 202111:02 amRNSHolding(s) in Company
2nd Mar 202112:12 pmRNSHolding(s) in Company
26th Feb 20214:20 pmRNSResult of Secondary Placing
26th Feb 20211:36 pmRNSProposed Secondary Placing
8th Feb 20214:30 pmRNSHolding(s) in Company
28th Jan 20217:00 amRNSSopheon extend innovation leadership with Simplot
25th Jan 20217:00 amRNSTrading Update
5th Nov 20207:00 amRNSRelease of Accolade version 13.2
12th Oct 20207:00 amRNSSeasoned Cloud & Industry Executive added to Team
9th Sep 20209:55 amRNSOrion Engineered Carbons works with Sopheon
1st Sep 202011:38 amRNSDirector Shareholdings
28th Aug 202012:39 pmRNSIssue of Equity
27th Aug 20207:00 amRNSInterim Results
30th Jul 20207:00 amRNSMondelez Partnership
13th Jul 202011:41 amRNSGrant of Options/PDMR Dealing
11th Jun 202011:28 amRNSResult of AGM
9th Jun 202012:00 pmRNSIssue of Equity & Director/PDMR Shareholding
28th May 20207:29 amRNSProgressive publishes new research
28th May 20207:00 amRNSNew Sopheon Release Integrating Microsoft Teams
15th May 202010:01 amRNSIssue of Equity
15th May 20207:00 amRNSAGM Notice and Update
3rd Apr 202011:17 amRNSDirector Shareholdings
25th Mar 20201:38 pmRNSIssue of Equity
19th Mar 20204:46 pmRNSIssue of Equity
19th Mar 20207:00 amRNSFinal Results
28th Jan 20209:05 amRNSSecond Price Monitoring Extn
28th Jan 20209:00 amRNSPrice Monitoring Extension
28th Jan 20207:00 amRNSTrading Update
10th Jan 20201:00 pmRNSIssue of Equity
11th Dec 20197:00 amRNSTrading Update
10th Oct 201912:00 pmRNSIssue of Equity
1st Oct 201912:00 pmRNSIssue of Equity
20th Sep 20194:45 pmRNSIssue of Equity
22nd Aug 20192:06 pmRNSSecond Price Monitoring Extn
22nd Aug 20192:01 pmRNSPrice Monitoring Extension
22nd Aug 201911:05 amRNSSecond Price Monitoring Extn
22nd Aug 201911:00 amRNSPrice Monitoring Extension
22nd Aug 20199:05 amRNSSecond Price Monitoring Extn
22nd Aug 20199:00 amRNSPrice Monitoring Extension
22nd Aug 20197:00 amRNSHalf-year Report
12th Aug 201910:45 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.